Get the Stockscreener App
9.80
2.87%
-0.29
After Hours:
9.99
0.19
+1.94%
Evolus Inc stock is traded at $9.80, with a volume of 1.36M.
It is down -2.87% in the last 24 hours and down -5.50% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$10.09
Open:
$10.21
24h Volume:
1.36M
Relative Volume:
1.62
Market Cap:
$768.13M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-9.0741
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-18.87%
1M Performance:
-5.50%
6M Performance:
-28.36%
1Y Performance:
-25.36%
1-Day Range:
$9.78
$10.61
1-Week Range:
$9.78
$12.24
52-Week Range:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.80 | 768.13M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its First-Quarter Report - simplywall.st
Evolus, Inc. (NASDAQ:EOLS) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo
Evolus, Inc. Reports Strong Q1 Growth Amid Challenges - TipRanks
EOLS Stock: Needham Reiterates Buy Rating with $22 Target | EOLS Stock News - GuruFocus
Evolus, Inc. (NASDAQ:EOLS) Q1 2025 Earnings Call Transcript - Insider Monkey
What Analysts Are Saying About Evolus Stock - Benzinga
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges - Yahoo
Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges By GuruFocus - Investing.com Canada
Evolus projects $345M-$355M revenue for 2025 with new product launches - MSN
Evolus, Inc. Reports Strong Q1 2025 Growth - TipRanks
Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Evolus Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Evolus Q1 2025 results miss forecasts, stock rises - Investing.com UK
EOLS Q1 Revenue Falls Short but Maintains Strong Momentum for 2025 | EOLS Stock News - GuruFocus
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
Evolus, Inc. SEC 10-Q Report - TradingView
Evolus Inc Q1 2025 Earnings: EPS Misses at -$0.30, Revenue Falls Short at $68.5 Million - GuruFocus
Evolus Reports First Quarter 2025 Results - Yahoo Finance
BioPharma Credit – Partial loan repayment and expanded Evolus facility - QuotedData
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost - GuruFocus
Evolus Secures New $250 Million Credit Facility - TipRanks
Evolus IncEnters New $250 Million Credit Facility With Pharmakon Advisors, Replacing Exisiting $125 Million Credit Agreement - marketscreener.com
Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility - Business Wire
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Evolus (EOLS) and Becton Dickinson (BDX) - The Globe and Mail
Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
When Will Evolus, Inc. (NASDAQ:EOLS) Breakeven? - simplywall.st
Evolus Inc (EOLS) Shares Gap Down to $11.115 on Apr 28 - GuruFocus
Midday Stock Roundup: FivePoint Rises on Earnings - Orange County Business Journal
Press Release Distribution & PR Platform - ACCESS Newswire
Evolus to Report First Quarter Financial Results on May 7, 2025 - BioSpace
Evolus: Two-Product Aesthetics Company With A Competitive Edge (NASDAQ:EOLS) - Seeking Alpha
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Evolus announces commercial launch of Evolysse - MSN
BTIG Initiates Coverage of Evolus (EOLS) with Buy Recommendation - Nasdaq
BTIG Initiates Evolus at Buy With $21 Price Target - marketscreener.com
Evolus initiated with a Buy at BTIG - TipRanks
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook | EOLS Stock News - GuruFocus
BTIG Initiates Coverage on Evolus (EOLS) with Optimistic Outlook - GuruFocus
Evolus Launches "Drop The F Word" To Redefine Aesthetic Injectables With Evolysse - Nasdaq
Evolus Announces Commercial Launch of Evolysse™ | EOLS Stock New - GuruFocus
Evolus Announces Commercial Launch of Evolysse™ - Yahoo Finance
Evolus Launches “Drop the F Word” Campaign in Advance of the Com - GuruFocus
Game-Changing Cold-X Technology: Evolus Revolutionizes Injectable Aesthetics with Natural Results - Stock Titan
Midday Stock Roundup: Evolus, ICU Medical down - Orange County Business Journal
H.C. Wainwright maintains Buy on Evolus stock with $27 target - Investing.com
H.C. Wainwright maintains Buy on Evolus stock with $27 target By Investing.com - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges - Investing.com Canada
Evolus stock hits 52-week low at $9.22 amid market challenges By Investing.com - Investing.com South Africa
Breaking Down Evolus: 8 Analysts Share Their Views - Benzinga
Investors Give Evolus, Inc. (NASDAQ:EOLS) Shares A 31% Hiding - simplywall.st
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):